Biocompatibles adds technology platform and two licences
This article was originally published in Clinica
Executive Summary
Biocompatibles, a darling of the UK stock market since its entry into the stent market late last year, has added a new technology platform and two new licences to its own coatings know-how based on phosphorylcholine (PC). Together with its 1996 results, it also reported that it launched its DivYsio stent in selected markets in February. The company's shares doubled since its share issue last November, closing at £10.90 on March 26th.
You may also be interested in...
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
ATAI Raises $125m Series C To Expand The Boundaries In Mental Health
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: